Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 30;7(11):ofaa462.
doi: 10.1093/ofid/ofaa462. eCollection 2020 Nov.

Peginterferon and Entecavir Combination Therapy Improves Outcome of Non-Early Response Hepatitis B e Antigen-Positive Patients

Lu Chen  1 , Lanyi Lin  1 , Huijuan Zhou  1 , Weiliang Tang  1 , Hui Wang  1 , Wei Cai  1 , Shisan Bao  2 , Simin Guo  1 , Qing Xie  1
Affiliations

Peginterferon and Entecavir Combination Therapy Improves Outcome of Non-Early Response Hepatitis B e Antigen-Positive Patients

Lu Chen et al. Open Forum Infect Dis. .

Erratum in

Abstract

Background: The efficacy of nucleot(s)ide analogs (NAs) and pegylated interferon (PegIFN) combination therapy for hepatitis B e antigen-positive (HBeAg+) patients is still controversial. Whether PegIFN and entecavir (ETV) combination therapy could provide a greater benefit for HBeAg+ patients was assessed.

Methods: Treatment-naïve HBeAg+ patients initiated on PegIFN alfa-2a (PegIFNα-2a) for 24 weeks without early response (early response: HBsAg <1500 IU/mL and hepatitis B virus [HBV] DNA <105 copies/mL) were recruited in the current study. Among total of 94 patients, 51 were continued on PegIFNα-2a monotherapy, and 43 were offered PegIFNα-2a and ETV combined therapy.

Results: Better outcomes in response to the combined therapy, compared with that of the monotherapy, were demonstrated, including more HBsAg decline and loss and HBV DNA decline and HBeAg clearance. Importantly, the patients with HBsAg levels between 1500 and 20 000 IU/mL initially or between 5000 and 20 000 IU/mL after 24 weeks of PegIFNα-2a benefitted more from the combined therapy, compared with those on monotherapy.

Conclusions: Combined therapy of PegIFNα-2a and ETV is more efficacious for HBeAg+ patients without early response to PegIFN monotherapy, and HBsAg levels are a good predictor of treatment outcomes.

Keywords: antiviral treatment; chronic hepatitis B; interferon; nucleos(t)ide analogues.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Treatment protocol of the study. Abbreviation: ETV, entecavir.
Figure 2.
Figure 2.
Flowchart of the study. Abbreviation: AE, adverse event.
Figure 3.
Figure 3.
The effect of HBsAg in the study. A, The HBsAg decline of the 2 groups from 0 to 96 weeks and 24 weeks post-EOT. B, The HBsAg value of the 2 groups at 48 and 96 weeks. C, HBsAg decline of the 2 groups with 48 and 96 weeks of treatment. Abbreviation: EOT, end of treatment.
Figure 4.
Figure 4.
Comparison of HBeAg clearance and HBV DNA decline/loss between the 2 groups. A, HBeAg clearance of the 2 groups at 96 weeks. B, HBV DNA decline of the 2 groups from week 0 to 96 weeks. C, HBV DNA clearance at 96 weeks of the 2 groups. Abbreviation: EOT, end of treatment.
Figure 5.
Figure 5.
Percentage of patients with HBsAg loss and HBeAg conversion at different time points. A, Percentage of patients with HBsAg loss at different time points. B, Percentage of patients with HBeAg conversion at different time points. Abbreviation: EOT, end of treatment.
Figure 6.
Figure 6.
The prediction value of HBsAg at 0 and 24 weeks. A, The response rate of all patients at 96 weeks with different HBsAg levels at 0 weeks. B, The response rate of patients in the 2 groups at 96 weeks with different HBsAg levels at 0 weeks. C, The response rate of patients in the 2 groups at 96 weeks with different HBsAg levels at 24 weeks. Abbreviation: HBV, hepatitis B virus.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Trépo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet 2014; 384:2053–63. - PubMed
    1. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57:167–85. - PubMed
    1. Sarin SK, Kumar M, Lau GK, et al. . Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016; 10:1–98. - PMC - PubMed
    1. Liaw YF, Kao JH, Piratvisuth T, et al. . Erratum to: Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012; 6:809–10. - PubMed
    1. Terrault NA, Lok ASF, McMahon BJ, et al. . Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018; 67:1560–99. - PMC - PubMed